HRP20050213A2 - 2,4-substituted indoles and their use as 5-ht6 modulators - Google Patents

2,4-substituted indoles and their use as 5-ht6 modulators

Info

Publication number
HRP20050213A2
HRP20050213A2 HR20050213A HRP20050213A HRP20050213A2 HR P20050213 A2 HRP20050213 A2 HR P20050213A2 HR 20050213 A HR20050213 A HR 20050213A HR P20050213 A HRP20050213 A HR P20050213A HR P20050213 A2 HRP20050213 A2 HR P20050213A2
Authority
HR
Croatia
Prior art keywords
modulators
substituted indoles
compound
formula
methods
Prior art date
Application number
HR20050213A
Other languages
English (en)
Inventor
Ann
James Weikert Robert
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20050213A2 publication Critical patent/HRP20050213A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj izum donosi spoj formule (I): njegovu farmaceutski prihvatljivu sol ili predlijek, pri čemu suR1, R2, R3, R4, p i n oni ovdje definirani. Ovaj izum također donosi pripravke koji sadrže, postupke za uporabu i postupke za pripravljanje spoja Formule (I).
HR20050213A 2002-09-17 2005-03-04 2,4-substituted indoles and their use as 5-ht6 modulators HRP20050213A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41148002P 2002-09-17 2002-09-17
PCT/EP2003/009969 WO2004026831A1 (en) 2002-09-17 2003-09-08 2,4-substituted indoles and their use as 5-ht6 modulators

Publications (1)

Publication Number Publication Date
HRP20050213A2 true HRP20050213A2 (en) 2006-12-31

Family

ID=32030683

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050213A HRP20050213A2 (en) 2002-09-17 2005-03-04 2,4-substituted indoles and their use as 5-ht6 modulators

Country Status (24)

Country Link
US (1) US7381739B2 (hr)
EP (1) EP1542973B1 (hr)
JP (1) JP4267573B2 (hr)
KR (1) KR100686757B1 (hr)
CN (1) CN1301970C (hr)
AR (1) AR041256A1 (hr)
AT (1) ATE402923T1 (hr)
AU (1) AU2003267063B2 (hr)
BR (1) BR0314363A (hr)
CA (1) CA2498946A1 (hr)
DE (1) DE60322551D1 (hr)
ES (1) ES2311721T3 (hr)
HK (1) HK1083497A1 (hr)
HR (1) HRP20050213A2 (hr)
MX (1) MXPA05002836A (hr)
NO (1) NO20050664L (hr)
NZ (1) NZ538047A (hr)
PA (1) PA8582101A1 (hr)
PL (1) PL376022A1 (hr)
RU (1) RU2326112C2 (hr)
TW (1) TWI250150B (hr)
UY (1) UY27979A1 (hr)
WO (1) WO2004026831A1 (hr)
ZA (1) ZA200501175B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
ES2274285T3 (es) * 2002-10-18 2007-05-16 F. Hoffmann-La Roche Ag 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6.
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
DE602004014190D1 (de) * 2003-12-23 2008-07-10 Lundbeck As Valby H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
AU2005244745B2 (en) * 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2010509259A (ja) * 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー インドール及びベンゾフラン２−カルボキサミド誘導体
EP2150112A1 (en) * 2007-04-26 2010-02-10 Merck & Co., Inc. 2-substituted indole derivatives as calcium channel blockers
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9499484B2 (en) * 2012-04-02 2016-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Indole, indoline derivatives, compositions comprising them and uses thereof
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) * 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
ES2181366T3 (es) 1998-06-30 2003-02-16 Lilly Co Eli Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina.
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
ATE337780T1 (de) * 2000-11-24 2006-09-15 Smithkline Beecham Plc Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物

Also Published As

Publication number Publication date
EP1542973B1 (en) 2008-07-30
ES2311721T3 (es) 2009-02-16
CN1681783A (zh) 2005-10-12
BR0314363A (pt) 2005-07-19
TWI250150B (en) 2006-03-01
MXPA05002836A (es) 2005-05-27
DE60322551D1 (de) 2008-09-11
CN1301970C (zh) 2007-02-28
ZA200501175B (en) 2007-03-28
KR20050057356A (ko) 2005-06-16
TW200413313A (en) 2004-08-01
WO2004026831A1 (en) 2004-04-01
US7381739B2 (en) 2008-06-03
NZ538047A (en) 2007-10-26
PA8582101A1 (es) 2004-04-23
RU2005111590A (ru) 2005-11-20
PL376022A1 (en) 2005-12-12
AU2003267063B2 (en) 2009-08-06
ATE402923T1 (de) 2008-08-15
AR041256A1 (es) 2005-05-11
RU2326112C2 (ru) 2008-06-10
AU2003267063A1 (en) 2004-04-08
UY27979A1 (es) 2004-03-31
HK1083497A1 (en) 2006-07-07
CA2498946A1 (en) 2004-04-01
JP2006502177A (ja) 2006-01-19
KR100686757B1 (ko) 2007-02-26
NO20050664L (no) 2005-04-15
US20040072844A1 (en) 2004-04-15
JP4267573B2 (ja) 2009-05-27
EP1542973A1 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
HRP20050775A2 (en) Quinolinone/benzoxazinone derivatives and uses thereof
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
SE0302760D0 (sv) New compounds
CY1111075T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τα παραγωγα της 3-αμινο-αζετιδινης, τα νεα παραγωγα τους και η προετοιμασια τους
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
NO20054787L (no) Indenderivater som farmasotiske midler
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
HRP20041030B1 (hr) Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
ATE300541T1 (de) Pyrazolopyridinderivate
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
HRP20070286T3 (hr) Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
NO20040881L (no) Orale antidiabetes midler.
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE318810T1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
ATE274515T1 (de) Pyrazolopyridinderivate
SG171472A1 (en) Substituted aniline derivatives
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080822

Year of fee payment: 6

OBST Application withdrawn